Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bayer Aktienges ADR (BAYRY)

Bayer Aktienges ADR (BAYRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 38,000,160
  • Shares Outstanding, K 3,929,696
  • Annual Sales, $ 50,432 M
  • Annual Income, $ -2,762 M
  • EBIT $ 4,261 M
  • EBITDA $ 9,427 M
  • 60-Month Beta 0.69
  • Price/Sales 0.76
  • Price/Cash Flow 2.58
  • Price/Book 1.11
  • Price/Earnings ttm 6.74
  • Earnings Per Share ttm 1.45
  • Most Recent Earnings $0.17 on 11/12/25
  • Next Earnings Date 11/11/25
  • Annual Dividend & Yield 0.02 (0.24%)
  • Most Recent Dividend 0.023 on 04/29/25
  • Sector Medical
  • INDUSTRY GROUPING Large Cap Pharma

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.15
  • Number of Estimates 1
  • High Estimate 0.15
  • Low Estimate 0.15
  • Prior Year 0.28
  • Growth Rate Est. (year over year) -46.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.4900 +29.11%
on 11/07/25
10.0300 -3.59%
on 12/02/25
+2.0900 (+27.57%)
since 11/05/25
3-Month
7.4790 +29.30%
on 11/04/25
10.0300 -3.59%
on 12/02/25
+1.4300 (+17.35%)
since 09/05/25
52-Week
4.7900 +101.88%
on 12/24/24
10.0300 -3.59%
on 12/02/25
+4.5460 (+88.72%)
since 12/05/24

Most Recent Stories

More News
Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome

BAY 3401016 is an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in Alport Syndrome...

BAYRY : 9.6700 (-1.02%)
BAYZF : 38.7000 (-2.74%)
BAYN : 0.0100 (unch)
RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints

Bayer revealed first results of the pediatric study from the pivotal clinical development program QUANTI for its low-dose MRI contrast agent QUANTI Pediatric evaluated the pharmacokinetics...

BAYRY : 9.6700 (-1.02%)
BAYZF : 38.7000 (-2.74%)
BAYN : 0.0100 (unch)
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia

Study further expands clinical development program of Bayer’s long-acting reversible intrauterine system Mirena® (levonorgestrel-releasing intrauterine system) 52 mg. Approximately...

BAYRY : 9.6700 (-1.02%)
BAYZF : 38.7000 (-2.74%)
BAYN : 0.0100 (unch)
Bayer Crop Science Canada Launches EverGol Rise for Enhanced User Experience in Pulse Disease Control

Bayer Crop Science Canada announced the launch of EverGol® Rise, setting a new standard in pulse disease control. Combining four different active ingredients, EverGol Rise brings enhanced disease control...

BAYRY : 9.6700 (-1.02%)
BAYZF : 38.7000 (-2.74%)
BAYN : 0.0100 (unch)
Bayer’s MEDRAD® Centargo Multi-Patient CT Injection System Now With A Wider Range of Compatible CT Contrast Agents and Presentations

Centargo compatible with Ultravist ® (iopromide), Isovue ® (iopamidol), Optiray ® (ioversol), Omnipaque™ (iohexol) and now, Visipaque™ (iodixanol) ...

BAYRY : 9.6700 (-1.02%)
BAYZF : 38.7000 (-2.74%)
BAYN : 0.0100 (unch)
Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention

Not intended for UK Media OCEANIC-STROKE demonstrates superiority of asundexian with antiplatelet therapy, showing significant reduction in ischemic stroke risk, without...

BAYRY : 9.6700 (-1.02%)
BAYZF : 38.7000 (-2.74%)
BAYN : 0.0100 (unch)
U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Following Priority Review, the U.S. FDA granted HYRNUO ® (sevabertinib) approval for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell...

BAYRY : 9.6700 (-1.02%)
BAYZF : 38.7000 (-2.74%)
BAYN : 0.0100 (unch)
Bayer Launches “Science Delivers” Campaign Celebrating the Transformative Power of Science

Multifaceted national initiative invites Americans to share stories of science’s impact and challenge misinformation

BAYRY : 9.6700 (-1.02%)
BAYZF : 38.7000 (-2.74%)
BAYN : 0.0100 (unch)
 KERENDIA® (finerenone) Meets Primary Endpoint in Phase III Clinical Trial for Adults with Type 1 Diabetes and Chronic Kidney Disease

The investigational FINE-ONE trial met its primary endpoint, demonstrating that finerenone led to a significant reduction in urine albumin-to-creatinine ratio (UACR), an important marker of cardiovascular...

BAYRY : 9.6700 (-1.02%)
BAYZF : 38.7000 (-2.74%)
BAYN : 0.0100 (unch)
Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause

This approval is supported by data from the Phase III OASIS clinical trial program evaluating Lynkuet for the treatment of moderate to severe hot flashes due to menopause 1 ...

BAYRY : 9.6700 (-1.02%)
BAYZF : 38.7000 (-2.74%)
BAYN : 0.0100 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses....

See More

Key Turning Points

3rd Resistance Point 9.8367
2nd Resistance Point 9.7833
1st Resistance Point 9.7267
Last Price 9.6700
1st Support Level 9.6167
2nd Support Level 9.5633
3rd Support Level 9.5067

See More

52-Week High 10.0300
Last Price 9.6700
Fibonacci 61.8% 8.0283
Fibonacci 50% 7.4100
Fibonacci 38.2% 6.7917
52-Week Low 4.7900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar